DERM Stock Forecast & Price Target

Journey Medical is supported by an Emrosi-led growth story that is still gaining traction, with 2Q26 revenue of $18.5M rising 23% year over year and adjusted EBITDA of $2.9M marking a third consecutive quarter of positive non-GAAP profitability. Demand indicators remain strong, as prescriptions increased about 10.0% sequentially in 3Q26 and 98.6% year over year, while unique prescribers reached more than 4,500 and quality commercial coverage improved to about 38% from 34% in 1Q26. Even with more conservative 2026 and 2027 revenue forecasts of $75.1M and $103.5M, the company still shows meaningful growth potential, aided by improving reimbursement, broader prescribing, and no incremental SG&A from Eurex Cream.

Journey Medical is exposed to a difficult competitive landscape, with branded and generic pressure in rosacea and other dermatology treatments limiting the durability of its revenue base. Its valuation already assumes an 11.7% WACC and a 16.0x exit multiple on 2031 estimates, yet the business still faces slower-than-expected Emrosi uptake, payer reimbursement pushback, and execution risk in scaling sales effectiveness. Additional downside comes from regulatory and patent litigation uncertainty, potential generic entry for Qbrexza, and the possibility that future capital raises to fund acquisitions or pipeline assets could dilute equity holders.